Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Feb 11, 2019 4:23pm

125 Views

Post# 29349224

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Sales Revenue (4147 TMB) January 2019

So the real problem is that steady growth in taimed revenue between June-Oct 2018 didnt reflect what was actually going on with patients. It got way, way ahead of it. If you look at Sept 2018 taimed revenue might only represent what might be happening now in actual sales. The flatness since then has been a correction, in fact its possible that flatness in Taimed revenue might continue another month or so. Couple that with the early statements about 100 and 200 patient milestones then there's been a huge disconnect. You could probably throw in the winter seasonal weakness as a huge red herring as well, really the 'weakness' happened before that.

We've been somewhat mis-lead over the past 6 months, its not just that our expectations were too high. Although whether any of that was deliberate idk.

That's history! We're maybe at 300+ patients, and we maybe experiencing an uptick and NASH maybe a thing. It would be great to get any or all of that confirmed with some solid statements.

PoorOpinion wrote:

PoorOpinion wrote: Sorry a vial should be about 700USD. Right?

So 60% of 2800 vials is about 1.1mil USD. Which equals 33mil TWD. So now the Taimed sales and actual monthly sales figures tally up quite well. The diversion they took in Oct is pretty much over.